预测性癌症诊断技术公司RHYTHM Biosciences Ltd (ASX股票代码:RHY) 股价异动，周三再度暴涨42.11%。

自周一披露ColoSTAT结直肠癌试剂盒的验证研究取得积极结果以来，RHY累计涨幅已达125%，且成交量连日显著放大。

RHY的ColoSTAT试剂盒目前处于商业化前的最终产品验证阶段，尽管相关研究尚未最终完成，有关初步300份患者血液样本的数据显示，ColoSTAT在检测所有阶段（I至IV期）结直肠癌方面均同样有效。

Rhythm临床顾问Andy Feber博士表示，能够在完整的肿瘤病程范围内表现出稳定性能，对于说明ColoSTAT具有临床实用价值十分重要。

RHY最新价0.135澳元，已发行股本2.84亿股，市值3835万澳元。截止上季度末公司账面现金结余140万澳元。

（图片来源：RHY公告）

（图片来源：RHY公告）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.